TG Therapeutics (NASDAQ: TGTX) net income
TG Therapeutics reported a net profit of $447.2m for fiscal 2025, 1,812.4% more than in fiscal 2024 ($23.4m). Its net margin was 72.6%. Earnings per share were $3.10.
TG Therapeutics has grown its net income for 2 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record. It reported a loss in 7 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $447.2m | +1,812.4% | 72.6% | $3.10 |
| 2024 | $23.4m | +84.5% | 7.1% | $0.16 |
| 2023 | $12.7m | — | 5.4% | $0.09 |
| 2022 | −$223.8m | — | −8,036.3% | −$1.65 |
| 2021 | −$348.1m | — | −5,204.1% | −$2.63 |
| 2020 | −$279.4m | — | −183,803.3% | −$2.42 |
| 2019 | −$172.9m | — | −113,730.9% | — |
| 2018 | −$173.5m | — | −114,132.9% | — |
| 2017 | −$118.5m | — | −77,944.7% | — |
| 2016 | −$78.3m | — | −51,482.2% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
TG Therapeutics net income compared with its sector
By net income for its latest fiscal year, TG Therapeutics ranks 63rd of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of TG Therapeutics, 72.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 61st | Molina Healthcare | $472.0m | 1.0% |
| 62nd | Medpace | $451.1m | 17.8% |
| 63rd | TG Therapeutics | $447.2m | 72.6% |
| 64th | Novavax | $440.3m | 39.2% |
| 65th | Align Technology | $410.4m | 10.2% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of TG Therapeutics
- How much did TG Therapeutics earn in fiscal 2025?
- TG Therapeutics reported a net profit of $447.2m for fiscal 2025. In fiscal 2024 it reported a net profit of $23.4m.
- What are the earnings per share of TG Therapeutics?
- They were $3.10 in fiscal 2025, compared with $0.16 in fiscal 2024.
- What is the net margin of TG Therapeutics?
- In fiscal 2025 its net profit was 72.6% of its revenue.
- What was the most profitable year for TG Therapeutics?
- Of its last 10 fiscal years, fiscal 2025, with $447.2m.
- Where does TG Therapeutics rank in its sector by net income?
- It ranks 63rd of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for TG Therapeutics come from?
- From the annual report (Form 10-K) that TG Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that TG Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on TG Therapeutics: the TG Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.